Optimal Use of Intravenous Tranexamic Acid for Hemorrhage Prevention in Pregnant Women. Issue 2 (24th June 2022)

• Record Type: Journal Article
• Authors: Ahmadzia, H.K.; Luban, N.L.C.; Li, S.; Guo, D.; Miszta, A.; Gobburu, J.V.S.; Berger, J.S.; James, A.H.; Wolberg, A.S.; van den Anker, J.
• Is Part Of: Obstetric anesthesia digest. Volume 42:Issue 2(2022)
• Page Start: 79
• Page End: 81
• Publication Date: 2022-06-24
• Subjects: Obstetric Hemorrhage; Anesthesia in obstetrics -- Periodicals; Anesthesia in obstetrics -- Abstracts -- Periodicals; 617.968205
• DOI: 10.1097/01.aoa.0000827880.37377.bd
• Languages: English
• ISSNs: 0275-665X

Abstract

Abstract : ( Am J Obstet Gynecol . 2021;225:85.e1–11) Postpartum hemorrhage (PPH) is a major cause of pregnancy-related death worldwide. Tranexamic acid (TXA) reduced death from bleeding by 31% when administered to women with PPH in the World Maternal Antifibrinolytic (WOMAN) trial. While some data suggests a low dose of TXA may achieve a therapeutic effect while minimizing exposure to the neonate, there is a lack of data on the use of TXA in pregnant women, including pharmacokinetic (PK) and pharmacodynamic (PD) data. This study aimed to evaluate the safety of using TXA in women undergoing cesarean delivery, including PK and PD outcomes, and to provide data on breast milk TXA concentration.